Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ATMSNASDAQ:BYSINASDAQ:CODXOTCMKTS:PURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATMSArtemis Therapeutics$0.00$0.11▼$5.00$55.79M-1.922,942 shsN/ABYSIBeyondSpring$1.67-6.2%$1.52$0.98▼$3.63$67.33M0.1329,398 shs23,301 shsCODXCo-Diagnostics$0.34-4.3%$0.39$0.28▼$2.23$11.41M0.84192,897 shs69,083 shsPUREPURE Bioscience$0.06+4.9%$0.07$0.05▼$0.16$6.90M0.3959,064 shs64,445 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATMSArtemis Therapeutics0.00%0.00%0.00%0.00%-94.75%BYSIBeyondSpring0.00%-1.47%+53.21%0.00%-31.56%CODXCo-Diagnostics0.00%-7.61%+0.92%-50.57%-72.14%PUREPURE Bioscience0.00%+4.93%+2.83%-9.66%-27.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATMSArtemis TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/ACODXCo-Diagnostics4.3784 of 5 stars3.55.00.04.42.60.01.3PUREPURE BioscienceN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATMSArtemis Therapeutics 0.00N/AN/AN/ABYSIBeyondSpring 0.00N/AN/AN/ACODXCo-Diagnostics 3.00Buy$5.501,518.12% UpsidePUREPURE Bioscience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATMS, PURE, BYSI, and CODX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025CODXCo-DiagnosticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025CODXCo-DiagnosticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.003/28/2025CODXCo-DiagnosticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$1.50 ➝ $1.00(Data available from 5/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATMSArtemis Therapeutics$310K0.00N/AN/A($0.01) per share0.00BYSIBeyondSpring$1.88M35.89N/AN/A($0.91) per share-1.84CODXCo-Diagnostics$3.92M2.91N/AN/A$2.81 per share0.12PUREPURE Bioscience$1.96M3.52N/AN/A($0.03) per share-2.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATMSArtemis Therapeutics-$1.36MN/A0.00N/AN/A-299.54%N/A-425.51%N/ABYSIBeyondSpring-$21.03MN/A0.00∞N/AN/AN/AN/AN/ACODXCo-Diagnostics-$35.33M-$1.24N/AN/AN/A-563.93%-54.94%-49.28%N/APUREPURE Bioscience-$3.35M-$0.04N/A∞N/A-183.96%N/A-352.61%N/ALatest ATMS, PURE, BYSI, and CODX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CODXCo-Diagnostics-$0.33-$0.24+$0.09-$0.24$0.38 million$0.05 million3/27/2025Q4 2024CODXCo-Diagnostics-$0.34-$0.36-$0.02-$0.36$0.38 million$0.15 million3/17/2025Q2 2025PUREPURE BioscienceN/A-$0.01N/A-$0.01N/A$0.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATMSArtemis TherapeuticsN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/ACODXCo-DiagnosticsN/AN/AN/AN/AN/APUREPURE BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATMSArtemis TherapeuticsN/A0.150.12BYSIBeyondSpringN/A1.82N/ACODXCo-DiagnosticsN/A6.926.70PUREPURE BioscienceN/A1.000.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATMSArtemis TherapeuticsN/ABYSIBeyondSpring40.29%CODXCo-Diagnostics14.99%PUREPURE BioscienceN/AInsider OwnershipCompanyInsider OwnershipATMSArtemis Therapeutics7.45%BYSIBeyondSpring29.31%CODXCo-Diagnostics8.40%PUREPURE Bioscience43.54%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATMSArtemis Therapeutics1112.03 million103.69 millionNot OptionableBYSIBeyondSpring8040.32 million27.59 millionOptionableCODXCo-Diagnostics10033.57 million29.98 millionOptionablePUREPURE Bioscience10111.86 million63.15 millionNot OptionableATMS, PURE, BYSI, and CODX HeadlinesRecent News About These CompaniesMeridian Bioscience Congratulates Catherine Lufkin For Receiving Pure Earth's 2025 "Force Of Nature" AwardMarch 6, 2025 | finance.yahoo.comPURE Bioscience Announces a New Distribution Agreement With Hydrite Chemical CompanyJanuary 21, 2025 | finance.yahoo.comPURE Bioscience Unveils New Brand IdentityJanuary 9, 2025 | businesswire.comPURE Bioscience Reports Fiscal First Quarter 2025 Financial ResultsDecember 16, 2024 | businesswire.comWorld’s First NMN Manufacturer, MIRAILAB BIOSCIENCE, Launches NMN Supplements and Cosmetics in UAEDecember 5, 2024 | businesswire.comPURE Bioscience announces distribution agreement with AFCONovember 26, 2024 | wattagnet.comPURE Bioscience Announces Distribution Agreement with AFCO, a Zep CompanyNovember 20, 2024 | finance.yahoo.comPURE Bioscience enters multi-year distribution agreement with Quip LabsNovember 6, 2024 | pharmabiz.comThis is what it’s really like to have OCD, according to 4 people living with itNovember 1, 2024 | tpr.orgPURE Bioscience Announces Distribution Agreement with Quip LaboratoriesNovember 1, 2024 | businesswire.comPURE Bioscience (OTC:PURE) Stock, Short Interest ReportNovember 1, 2024 | benzinga.comPURE Bioscience Reports Fiscal 2024 Financial ResultsOctober 29, 2024 | businesswire.comPURE Bioscience, Madison Chemical Announce Distribution AgreementOctober 28, 2024 | cleanlink.comPURE Bioscience Announces Distribution Agreement with Madison Chemical Co., Inc.October 22, 2024 | finance.yahoo.comFunctional Extracts Market Key Trends, Health Applications, and Industry Growth 2032October 21, 2024 | fmiblog.comMaterials of the future can be extracted from wastewaterOctober 20, 2024 | msn.comDestiny: Rising - Five things we want to see in NetEase's upcoming mobile shooterOctober 14, 2024 | pocketgamer.comOTC Markets Hosts Virtual Investor Presentation with Eric Leire, Founder & CEO of Genflow Biosciences, and Brad Sorensen, Senior Analyst at Zacks SCROctober 14, 2024 | msn.comAdvancing gene therapy for kidney disease, Purespring adds £80MOctober 11, 2024 | bioworld.comPURE Bioscience announces SDC distribution agreement with Zee CompanyOctober 11, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATMS, PURE, BYSI, and CODX Company DescriptionsArtemis Therapeutics OTCMKTS:ATMSArtemis Therapeutics, Inc. is a biopharmaceutical company. It develops new treatments for serious and life-threatening infections. It Includes cytomegalovirus and malaria. The company was founded on April 22, 1997 and was headquartered in New York, NY.BeyondSpring NASDAQ:BYSI$1.67 -0.11 (-6.18%) As of 05/9/2025 03:51 PM EasternBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Co-Diagnostics NASDAQ:CODX$0.34 -0.02 (-4.31%) As of 05/9/2025 04:00 PM EasternCo-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.PURE Bioscience OTCMKTS:PURE$0.06 +0.00 (+4.93%) As of 05/9/2025 03:44 PM EasternPURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
